An independent clinical review of Women's International Pharmacy, its compounded BHRT model, costs, legitimacy, and how it compares to alternatives, prepared by the HealthRX.com Editorial Team.
An evidence-based patient profile for Women's International Pharmacy, covering compounded BHRT candidacy, safety data, cost, and how it compares to FDA-approved alternatives.
Amlodipine can cause dose-related ankle and leg swelling. Learn why it happens, what 5 mg and 10 mg trial rates mean, red flags, and evidence-based options.
Eliquis can cause bleeding. Learn how to separate small stable bruising from bleeding that needs same-day or emergency care, plus reversal evidence.
Learn how metoprolol withdrawal differs from reassessing long-term treatment, and what ABYSS and SMART-DECISION found after a previous heart attack.
Crestor can be taken at night or in the morning. See what its 19-hour half-life, a direct crossover trial, antacid timing, lab tests, and side effects mean for your routine.
Yes, lisinopril can be taken at night, but bedtime is not universally better. Compare TIME, BedMed, the current label, safety, and a practical timing decision.
A detailed look at whether amlodipine causes weight gain, what the clinical data show, how edema gets mistaken for fat gain, and what to do if your weight changes on this medication.
Crestor (rosuvastatin) can cause muscle pain in a small but real percentage of users. Learn the rates, warning signs, risk factors, and exactly when to call your doctor.
Eliquis can be taken with or without food. See what changes when apixaban is swallowed whole, crushed in water, mixed with applesauce, or given by tube.
Lipitor starts acting before you can measure its full effect. See the evidence-based timeline for LDL change, lab follow-up, dose decisions, and cardiovascular benefit.
Metoprolol is beta-1 selective, not a beta-2 blocker. See why it's preferred in asthma/PVD patients and how selectivity changes at higher doses.
Bempedoic acid inhibits ATP-citrate lyase to lower LDL-C 21-24% alone or 36-38% with ezetimibe (Nexlizet), cutting MACE 13% in statin-intolerant patients.
Bisoprolol pairs safely with atorvastatin or rosuvastatin, addressing heart rate and lipid risk together. See dosing, interactions, and monitoring guidance.
Carvedilol is not a statin. It's a beta-blocker for heart failure and hypertension, often taken with statins like atorvastatin for full cardiometabolic care.
180/120 mmHg is a hypertensive crisis. Learn AHA symptoms that mean call 911 vs same-day care, and why BP drops slowly in an emergency.
A complete clinical guide to inclisiran (Leqvio), a twice-yearly PCSK9 siRNA injection, compared with atorvastatin, rosuvastatin, simvastatin, and ezetimibe for LDL-C lowering and cardiovascular risk reduction.
A guide to lisinopril, atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin (Zocor), and ezetimibe (Zetia): how each drug works, what the trials show, dosing, side effects, and how they fit together in a cardiometabolic treatment plan.
Carvedilol blocks alpha-1 and beta receptors; metoprolol succinate is beta-1 selective. Both cut heart failure mortality by about 34-35% in trials.
Niacin raises HDL and cuts triglycerides, but AIM-HIGH and HPS2-THRIVE found no added heart benefit over statins like Lipitor, plus more side effects.
A guide to rivaroxaban (Xarelto): approved indications, dosing by indication, bleeding risks, drug interactions with statins like atorvastatin and rosuvastatin, and what the ROCKET AF and EINSTEIN trials actually showed.
Nexlizet (bempedoic acid) lowers LDL-C 18-25%, less than statins' 30-55%, but cuts CV events per CLEAR Outcomes for statin-intolerant patients.
Observational data link PDE5 inhibitors to lower mortality after a first heart attack but cannot show tadalafil prevents death.
A guide to tadalafil dosing in patients 65 and older, covering starting doses, renal and hepatic adjustments, drug interactions, falls risk, and when to reconsider treatment.
A look at how tadalafil affects mood, depression, anxiety, and psychological well-being, with primary-literature citations and clinical dosing guidance.
The Cialis label gives no genotype-based dose. Its limits depend on the indication, kidney and liver function, and CYP3A4 inhibitor drugs.
A guide to how tadalafil (Cialis) affects erectile function, libido, orgasm, and partner satisfaction, with primary-literature citations and practical dosing guidance.
A deep dive into how tadalafil affects sleep architecture, nocturnal erections, sleep apnea, and overnight PDE5 inhibition. Includes clinical trial data, dosing considerations, and practical guidance.
A clinical reference on CJC-1295 modified GRF use in adults aged 65 and older, covering dosing considerations, renal and hepatic factors, fall risk, IGF-1 monitoring, and deprescribing, for editorial and qualified clinical review.
CJC-1295 has no safety data in adults over 65. This page covers what published trials and FDA reported, the stopped 2006 trial and regulatory status.
A synthesis of CJC-1295 (modified GRF) real-world evidence, mechanism, dosing, safety signals, and registry data, with PubMed-cited primary sources throughout.
FDA found no study of CJC-1295 in people with a disease. This review covers the healthy-volunteer data and the HIV trials that ended early.
A prescriber-level guide to recognizing, grading, and managing adverse events from finasteride and dutasteride, with dosing tables, monitoring schedules, and evidence-based mitigation strategies.
Complete DDI table for finasteride and dutasteride, with mechanism-based interaction data, prescribing guidance, and clinical pearls at MD/PharmD level.
A prescriber-level guide to finasteride vs. Dutasteride: mechanism, isoenzyme coverage, approved indications, dosing, side-effect profiles, and evidence-based selection criteria for BPH and androgenetic alopecia.
A full clinical reference on aromatase inhibitor drug class pharmacology, prescribing, and the complete monitoring bundle, bone density, lipids, joint symptoms, estradiol levels, and safety thresholds, written at MD/PharmD level.
A prescriber-level guide to aromatase inhibitor drug classes, dosing titration approaches, and tapering considerations for breast cancer and off-label estrogen-excess management in men, with an evidence-boundary map and a clinician-discussion checklist.
A prescriber-level guide to anastrozole, letrozole, and exemestane, covering pharmacology, clinical trial data, dosing, and agent selection criteria for breast cancer and off-label estrogen management.
A clinical-level review of bisphosphonate drug-drug interactions, pharmacokinetics, dosing rules, and prescribing guidance for alendronate, zoledronic acid, risedronate, ibandronate, and pamidronate, with a full DDI table and primary-source citations.
A prescriber-level guide to copper peptide drug class pharmacology, compounding regulations, billing codes, and prior-authorization strategy for GHK-Cu and related peptides.
A clinical-level review of copper peptide pharmacology, dosing, and safety across special populations including pregnancy, pediatrics, renal impairment, and older adults. Written for prescribers and dispensing clinicians.
A prescriber-level guide to recognizing, grading, and managing adverse events from systemic estrogen therapy, covering VTE, endometrial risk, cardiovascular effects, and monitoring protocols with evidence from WHI, PEPI, and current NAMS/ACOG guidelines.
A prescriber-level monograph on systemic estrogens: pharmacology, formulations, dosing, indications, contraindications, monitoring, and key trial data for menopausal HRT and beyond.
A prescriber-level review of cholesterol absorption inhibitors, focusing on ezetimibe and emerging agents, with evidence-based guidance on when and how to add them to statin or non-statin regimens.
A board-reviewed prescriber guide to the GHRH analog drug class covering sermorelin, tesamorelin, and CJC-1295. Includes baseline labs, on-therapy monitoring intervals, dose-adjustment criteria, and safety thresholds with primary-source citations.
A clinical guide to GHRH analog selection, sermorelin, tesamorelin, CJC-1295, and modified peptides, covering pharmacology, dosing, indications, and how to choose between agents for GH axis stimulation.
A prescriber-level guide to managing adverse events with triple receptor agonists (GLP-1/GIP/glucagon), including retatrutide. Covers GI toxicity, cardiovascular monitoring, hepatic considerations, and dose-titration protocols grounded in Phase 2/3 trial data.
A prescriber-level guide to titrating and tapering retatrutide and other GLP-1/GIP/glucagon triple agonists, including dose schedules, stopping rules, and restart protocols based on current trial data.
GI side effects hit 30-50% of GLP-1 users and cause most early stops. See dose escalation, stopping rules, and pancreatitis risk factors to keep patients on therapy.
A clinical guide to selecting among GLP-1 receptor agonists, semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, based on weight, CV risk, renal function, dosing frequency, and cost. Written for prescribers and clinical pharmacists.
A prescriber-level guide to identifying, grading, and managing adverse events associated with GH secretagogue therapy, including ipamorelin, sermorelin, CJC-1295, and MK-677. Covers mechanism-based toxicity, monitoring schedules, and dose-adjustment algorithms.
A physician-level guide to monitoring patients on GH secretagogues (ipamorelin, CJC-1295, MK-677, GHRP-2, GHRP-6). Covers baseline labs, on-therapy intervals, dose titration, safety signals, and discontinuation criteria with primary-source citations.
Edema, paresthesia, and insulin resistance risk vary by age, sex, and comorbidity with GH secretagogues; see population-specific dosing and monitoring guidance.
A prescriber-level guide to BPC-157 and TB-500 dosing, titration schedules, tapering protocols, and the clinical rationale behind each step, with primary-source citations throughout.
A prescriber-level guide to basal insulin analog titration and tapering algorithms for T1D and T2D, including starting doses, adjustment protocols, and deprescribing strategies backed by clinical trial data.
Basaglar (glargine U-100) and Toujeo (glargine U-300) differ in concentration, duration, and hypoglycemia risk. Compare profiles to pick the right agent.
A clinician-level guide to preventing, recognizing, and managing adverse events with rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart, inhaled insulin). Includes hypoglycemia protocols, injection-site reactions, and dosing frameworks.
A prescriber-level review of rapid-acting insulin analogs (lispro, aspart, glulisine, ultra-rapid formulations) across pediatric, pregnant, elderly, and renal/hepatic-impaired populations, with dosing guidance and key trial data.
A clinical guide to choosing among lispro, aspart, glulisine, faster aspart, and ultra-rapid lispro for prandial insulin coverage. Written at MD/PharmD level with head-to-head trial data, dosing nuances, and practical switching guidance.
A clinical-level review of meglitinide adverse events, prescribing protocols, hypoglycemia management, drug interactions, and patient selection for repaglinide and nateglinide.